Literature DB >> 6136450

Influence of cigarette smoking on healing and relapse in duodenal ulcer disease.

M G Korman, J Hansky, E R Eaves, G T Schmidt.   

Abstract

There are conflicting reports on the influence of cigarette smoking on healing in patients with duodenal ulcer; some studies show an adverse effect on healing rate and others no effect. This study reports the influence of smoking on short-term healing and relapse rate in 135 patients with duodenal ulcer who were treated with cimetidine (90), ranitidine (25), and oxmetidine (20), all powerful H2-receptor antagonists. Ulcer healing and relapse were documented endoscopically and all studies were performed in a double-blind manner. In the short term, 95% of nonsmokers healed compared with 63% smokers (p less than 0.01) and there was a positive correlation between failure to heal and number of cigarettes smoked. During a 12-mo follow-up examination after healing and on no treatment, 53% of nonsmokers and 84% of smokers relapsed (p less than 0.01). These results show that smoking adversely affects healing of duodenal ulcer with H2-receptor antagonists and that continued smoking leads to a higher relapse rate.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6136450

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  47 in total

1.  Smoking and ulcer healing.

Authors:  A Duggan; N Rutherford
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  Peptic ulcer disease: absence of antibodies stimulating the histamine sensitive adenylate cyclase of gastric mucosal cells.

Authors:  P Burman; S Mårdh; L Lööf; J Naesdal; F A Karlsson
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

Review 3.  Smoking and the digestive system.

Authors:  T Kamada; S Kawano; S Tsuji
Journal:  J Gastroenterol       Date:  1995-12       Impact factor: 7.527

Review 4.  Histamine H2-receptor antagonists versus prostaglandins in the treatment of peptic ulcer disease.

Authors:  J G Penston; K G Wormsley
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

5.  Anti-ulcer therapy. Past to present.

Authors:  A Bettarello
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

6.  Acute treatment of duodenal ulcer: a multicentre study to compare ranitidine 150 mg twice daily with ranitidine 300 mg once at night.

Authors:  F I Lee; P I Reed; J P Crowe; R L McIsaac; J R Wood
Journal:  Gut       Date:  1986-09       Impact factor: 23.059

Review 7.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

8.  Does seropositivity for Helicobacter pylori antibodies increase outpatient costs for gastric and duodenal ulcer or inflammation?

Authors:  Akira Babazono; Motonobu Miyazaki; Hiroshi Une; Eiji Yamamoto; Toshihide Tsuda; Yoshio Mino; Alan L Hillman
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 9.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

10.  Clinical markers of slow healing and relapsing gastric ulcer.

Authors:  G Battaglia; F Di Mario; A Piccoli; F Vianello; F Farinati; R Naccarato
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.